National Academies Press: OpenBook
« Previous: Appendix A: Statement of Task
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×

Appendix B

Workshop Agenda

JULY 21, 2020

10:00 a.m. Welcome and Opening Remarks
SARA ROSENBAUM, THE GEORGE WASHINGTON UNIVERSITY PLANNING COMMITTEE CHAIR
Sponsor Remarks from the Social Security Administration
MARK WARSHAWSKY, SOCIAL SECURITY ADMINISTRATION
10:15 a.m. Session 1: Overview of Biomarkers
Moderator:
SARA ROSENBAUM, THE GEORGE WASHINGTON UNIVERSITY
Overview of Terminology and Biomarker Use in Clinical Decision Making
JOSEPH MENETSKI, FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH
Where Do Biomarkers Fit When Trying to Relate Health to Function?
AMY WAGNER, UNIVERSITY OF PITTSBURGH
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×
Panel Discussion
11:15 a.m. Break
11:30 a.m. Session 2: Bioethical and Legal Considerations with the Use of Biomarkers to Establish Presence and Severity of Impairments
Moderator:
SARAH RUIZ, NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH
Panelists
JEROME BICKENBACH, UNIVERSITY OF LUCERNE

JUDITH COOK, UNIVERSITY OF ILLINOIS AT CHICAGO CENTER ON MENTAL HEALTH SERVICES RESEARCH AND POLICY

KRISTI KIRSCHNER, UNIVERSITY OF ILLINOIS COLLEGE OF MEDICINE

ANDREW PETERSON, GEORGE MASON UNIVERSITY

Panel Discussion
12:15 p.m. Lunch Break
12:45 p.m. Session 3: State of the Science on Biomarkers to Establish Presence and Severity of Impairments:
Part I
(major depression, post-traumatic stress disorder, and schizophrenia)
Moderator: LINDA BRADY, NATIONAL INSTITUTES OF HEALTH
Panelists

MADHUKAR TRIVEDI, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER AT DALLAS

AMIT ETKIN, STANFORD UNIVERSITY AND ALTO NEUROSCIENCE

JEFFREY LIEBERMAN, COLUM BIA UNIVERSITY

PHILIP HARVEY, UNIVERSITY OF MIAMI

Panel Discussion
2:20 p.m. Break
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×
2:35 p.m. Session 3: State of the Science on Biomarkers to Establish Presence and Severity of Impairments:
Part II
(arthritis, chronic pain, and fibromyalgia)
Moderator: ROBERT WALLACE, UNIVERSITY OF IOWA
Panelists
DANIEL CLAUW, UNIVERSITY OF MICHIGAN

JOAN BATHON, COLUM BIA UNIVERSITY

VIRGINIA BYERS KRAUS, DUKE MOLECULAR PHYSIOLOGY INSTITUTE

GWENDOLYN SOWA, UNIVERSITY OF PITTSBURGH

Panel Discussion
4:15 p.m. Session 5: Reactor Panel
Moderator:
SARA ROSENBAUM, THE GEORGE WASHINGTON UNIVERSITY
Panelists

BETTY DIAMOND, HOFSTRA NORTHWELL SCHOOL OF MEDICINE

SARAH MORRIS, NATIONAL INSTITUTES OF HEALTH

RALPH NITKIN, NATIONAL INSTITUTES OF HEALTH

IRA SHOULSON, UNIVERSITY OF ROCHESTER

4:45 p.m. Public Comment
4:55 p.m. Workshop Wrap-Up
SARA ROSENBAUM, THE GEORGE WASHINGTON UNIVERSITY PLANNING COMMITTEE CHAIR
5:00 p.m. Adjourn
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×

This page intentionally left blank.

Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×
Page 55
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×
Page 56
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×
Page 57
Suggested Citation:"Appendix B: Workshop Agenda." National Academies of Sciences, Engineering, and Medicine. 2020. Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/25926.
×
Page 58
Next: Appendix C: Biographical Sketches of Workshop Speakers and Planning Committee Members »
Examining the Use of Biomarkers in Establishing the Presence and Severity of Impairments: Proceedings of a Workshop Get This Book
×
Buy Paperback | $45.00 Buy Ebook | $36.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

As part of the overall disability determination process, the Social Security Administration uses a step-by-step approach to understand how severe an individual's condition is and whether it meets program criteria for disability. The use of various types of biomarkers has been suggested as a way to strengthen the amount and quality of objective evidence available to the review process.

At the request of the Social Security Administration, the National Academies of Sciences, Engineering, and Medicine's Board on Health Care Services organized a virtual workshop on July 21, 2020, titled The State of the Science of the Use of Biomarkers to Establish the Presence and Severity of Impairments. Workshop discussions focused on the current and potential uses for biomarkers; explored legal and ethical implications associated with biomarker use in clinical decision making; and considered the possible uses of nongenetic biomarkers as tools for the diagnosis or prognosis of the severity of specific physical and mental impairments. This publication summarizes the presentations and discussion of the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!